Type I interferons in systemic autoimmunity
Type I interferons in systemic autoimmunity
复制标题
DOI：
10.3109/08916930903510872
复制
发表时间：
2010-04-01
期刊：
影响因子：
3.5
通讯作者：
Tincani, Angela
中科院分区：
文献类型：
--
作者：
Sozzani, Silvano;Bosisio, Daniela;Tincani, Angela
I型干扰素(IFN-I)于1957年首次被描述为一种在体外引起病毒耐药的可溶性因子。今天，众所周知，干扰素-I家族由多种细胞因子组成，它们对血管生成、细胞生长、纤维化和细胞凋亡具有不同的调节作用。然而，干扰素-I最重要的功能之一是能够触发一系列复杂的细胞反应，从而产生宿主保护性的抗病毒反应。正因为如此，干扰素-I可以被认为是保护性免疫反应的“导向器”。最近在患有不同自身免疫性疾病的患者中发现了所谓的干扰素信号，这突显了它在这些疾病的发病机制中可能发挥的作用。另一方面，据报道，干扰素-α/β对某些自身免疫性和感染性疾病有疗效，对常规治疗无效。在这些情况下，接受治疗的患者通常会开始或增加自身抗体的产生，以支持干扰素作为自身免疫反应的诱导者的作用。在这篇综述中，我们将重点介绍关于干扰素-I生物学的最新进展，重点是一些自身免疫性疾病的诱发，如系统性红斑狼疮、系统性硬化症、类风湿性关节炎、皮肤病/多发性粘膜炎和干燥综合征。
Type I IFN (IFN-I) was firstly described in 1957 as a soluble factor responsible for viral resistance in vitro. Today, it is well known that the IFN-I family comprises a wide number of cytokines with different modulatory effects on angiogenesis, cell growth, fibrosis, and apoptosis. However, one of the most important functions of IFN-I is the capability to trigger a complex array of cellular responses that result in a host-protective antiviral response. For this reason, IFN-I can be considered a "director" of protective immune responses. The recent finding of the so-called interferon signature in patients suffering from different autoimmune diseases has underlined its possible role in the pathogenesis of these diseases. On the other hand, IFN-alpha/beta is reported to be efficacious in the treatment of some autoimmune and infectious diseases not responsive to conventional therapy. On these occasions, the treated patients often start or increase autoantibody production supporting the role of IFN as inducer of an autoimmune response. In this review, we will underline recent acquisitions about IFN-I biology, with a focus on the relevance of the induction of some autoimmune diseases, such as systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, dermato/polymiositis, and Sjogren's syndrome.